A study showed that LYPD3 stimulates proliferation, migration, invasion and drug resistance of pancreatic ductal adenocarcinoma (PDAC) cells by interacting with AGR2 [41]. Here, LYPD3 is linked to pancreatic ductal adenocarcinoma.